Literature DB >> 27644018

Expanding the phenotype of Triple X syndrome: A comparison of prenatal versus postnatal diagnosis.

Kristen Wigby1,2, Cheryl D'Epagnier1, Susan Howell1,3, Amy Reicks4, Rebecca Wilson3, Lisa Cordeiro1, Nicole Tartaglia5,6.   

Abstract

Triple X syndrome (47, XXX) occurs in approximately 1:1,000 female births and has a variable phenotype of physical and psychological features. Prenatal diagnosis rates of 47, XXX are increasing due to non-invasive prenatal genetic testing. Previous studies suggest that prenatal diagnosed females have better neurodevelopmental outcomes. This cross-sectional study describes diagnosis, physical features, medical problems, and neurodevelopmental features in a large cohort of females with 47, XXX. Evaluation included review of medical and developmental history, physical exam, cognitive, and adaptive testing. Medical and developmental features were compared between the prenatal and postnatal diagnosis groups using rate calculations and Fisher's exact test. Cognitive and adaptive tests scores were compared using t-tests. Seventy-four females age 6 months-24 years (mean 8.3 years) participated. Forty-four (59.5%) females were in the prenatal diagnosis group. Mean age of postnatal diagnosis was 5.9 years; developmental delay was the most common indication for postnatal genetic testing. Common physical features included hypertelorism, epicanthal folds, clinodactyly, and hypotonia. Medical problems included dental disorders (44.4%), seizure disorders (16.2%), genitourinary malformations (12.2%). The prenatal diagnosis group had higher verbal (P < 0.001), general ability index (P = 0.004), and adaptive functioning scores (P < 0.001). Rates of ADHD (52.2% vs. 45.5%, P = 0.77) and learning disabilities (39.1% vs. 36.3%, P = 1.00) were similar between the two groups. These findings expand on the phenotypic features in females with Triple X syndrome and support that prenatally ascertained females have better cognitive and functional outcomes. However, prenatally diagnosed females are still at risk for neurodevelopmental disorders. Genetic counseling and treatment recommendations are summarized.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  47, XXX; sex chromosome aneuploidy (SCA); triple X syndrome; triplo-X; trisomy X

Mesh:

Year:  2016        PMID: 27644018      PMCID: PMC6501572          DOI: 10.1002/ajmg.a.37688

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  41 in total

1.  Volumetric magnetic resonance imaging study of the brain in subjects with sex chromosome aneuploidies.

Authors:  M M Warwick; G A Doody; S M Lawrie; J N Kestelman; J J Best; E C Johnstone
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

2.  Development of a general ability index for the Wechsler Adult Intelligence Scale--Third Edition.

Authors:  D S Tulsky; D H Saklofske; C Wilkins; L G Weiss
Journal:  Psychol Assess       Date:  2001-12

3.  Age at menarche and racial comparisons in US girls.

Authors:  William Cameron Chumlea; Christine M Schubert; Alex F Roche; Howard E Kulin; Peter A Lee; John H Himes; Shumei S Sun
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

4.  The association between triple X and psychosis.

Authors:  W J Woodhouse; A J Holland; G McLean; A M Reveley
Journal:  Br J Psychiatry       Date:  1992-04       Impact factor: 9.319

5.  47,XXX in an adolescent with premature ovarian failure and autoimmune disease.

Authors:  C M Holland
Journal:  J Pediatr Adolesc Gynecol       Date:  2001-05       Impact factor: 1.814

6.  Electroencephalographic and epileptic patterns in X chromosome anomalies.

Authors:  Salvatore Grosso; Mariangela A Farnetani; Rosanna Maria Di Bartolo; Rosario Berardi; Lucia Pucci; Rosa Mostardini; Cecilia Anichini; Gabriella Bartalini; Daniela Galimberti; Guido Morgese; Paolo Balestri
Journal:  J Clin Neurophysiol       Date:  2004 Jul-Aug       Impact factor: 2.177

7.  Tall stature as presenting symptom in a girl with triple X syndrome.

Authors:  B U Liebezeit; T R Rohrer; H Singer; H G Doerr
Journal:  J Pediatr Endocrinol Metab       Date:  2003-02       Impact factor: 1.634

8.  Prevalence of the triple X syndrome in phenotypically normal women with premature ovarian failure and its association with autoimmune thyroid disorders.

Authors:  Ravinder Goswami; Deepti Goswami; Madhulika Kabra; Nandita Gupta; Sudhisha Dubey; Vatsala Dadhwal
Journal:  Fertil Steril       Date:  2003-10       Impact factor: 7.329

9.  Fifty-one prenatally diagnosed children and adolescents with sex chromosome abnormalities.

Authors:  Mary G Linden; Bruce G Bender
Journal:  Am J Med Genet       Date:  2002-06-01

10.  Prognosis of prenatally diagnosed children with sex chromosome aneuploidy.

Authors:  A Robinson; B G Bender; M G Linden
Journal:  Am J Med Genet       Date:  1992-10-01
View more
  19 in total

Review 1.  A review of neurocognitive functioning and risk for psychopathology in sex chromosome trisomy (47,XXY, 47,XXX, 47, XYY).

Authors:  Sophie van Rijn
Journal:  Curr Opin Psychiatry       Date:  2019-03       Impact factor: 4.741

2.  Current survey of early childhood intervention services in infants and young children with sex chromosome aneuploidies.

Authors:  Talia Thompson; Susan Howell; Shanlee Davis; Rebecca Wilson; Jennifer Janusz; Richard Boada; Laura Pyle; Nicole Tartaglia
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-05-25       Impact factor: 3.908

Review 3.  When the Lyon(ized chromosome) roars: ongoing expression from an inactive X chromosome.

Authors:  Laura Carrel; Carolyn J Brown
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-11-05       Impact factor: 6.237

Review 4.  Early neurodevelopmental and medical profile in children with sex chromosome trisomies: Background for the prospective eXtraordinarY babies study to identify early risk factors and targets for intervention.

Authors:  Nicole Tartaglia; Susan Howell; Shanlee Davis; Karen Kowal; Tanea Tanda; Mariah Brown; Cristina Boada; Amanda Alston; Leah Crawford; Talia Thompson; Sophie van Rijn; Rebecca Wilson; Jennifer Janusz; Judith Ross
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-06-07       Impact factor: 3.908

5.  Novel biallelic ATM mutations coexist with a mosaic form of triple X syndrome in an 11-year-old girl at remission after T cell acute leukemia.

Authors:  Svetlana O Sharapova; Alena V Valochnik; Irina E Guryanova; Inga S Sakovich; Olga V Aleinikova
Journal:  Immunogenetics       Date:  2018-02-28       Impact factor: 2.846

Review 6.  Clinical spectrum of female genital malformations in prenatal diagnosis.

Authors:  Michael R Mallmann; Ulrich Gembruch
Journal:  Arch Gynecol Obstet       Date:  2022-02-27       Impact factor: 2.344

7.  Supporting students with sex chromosome aneuploidies in educational settings: Results of a nationwide survey.

Authors:  Talia Thompson; Shanlee Davis; Jennifer Janusz; Erin Frith; Laura Pyle; Susan Howell; Richard Boada; Rebecca Wilson; Nicole Tartaglia
Journal:  J Sch Psychol       Date:  2022-06-28

8.  Family experiences and attitudes about receiving the diagnosis of sex chromosome aneuploidy in a child.

Authors:  Kirsten A Riggan; Sharron Close; Megan A Allyse
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-03-17       Impact factor: 3.908

Review 9.  Diagnostic cytogenetic testing following positive noninvasive prenatal screening results of sex chromosome abnormalities: Report of five cases and systematic review of evidence.

Authors:  Xiaolei Xie; Weihe Tan; Fuguang Li; Eric Carrano; Paola Ramirez; Autumn DiAdamo; Brittany Grommisch; Katherine Amato; Hongyan Chai; Jiadi Wen; Peining Li
Journal:  Mol Genet Genomic Med       Date:  2020-05-08       Impact factor: 2.183

10.  The behavioral profile of children aged 1-5 years with sex chromosome trisomy (47,XXX, 47,XXY, 47,XYY).

Authors:  Evelien Urbanus; Hanna Swaab; Nicole Tartaglia; Lisa Cordeiro; Sophie van Rijn
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-05-20       Impact factor: 3.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.